Tracing the relevance of TP53-related pathways to the gene levels, roles for TP53 and MDM2 have been previously established in prostate cancer disease progression32,34–40, we also observed alterations in MDM4 that contributed substantially to this network convergence. This evidence concerns the gene MDM2 and prostate carcinoma.